pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)
MSD Merck Sharp
Merck Sharp and Dohme
MSD Merck Sharp clinical programs — 217 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- WERFTESTRASSE 4, Lucerne, 6005, ch
- Employees
- 61
- Programs
- 217
- Drugs
- 180
- Patents
- 0
MSD Merck Sharp projects
217 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.
MSD Merck Sharp has 217 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A clinical trial of MK-6050 in healthy participants (MK-6050-002)
Merck Sharp and Dohme
Hidradenitis suppurativa
1 trial -
A clinical trial of MK-6916 in healthy participants (MK-6916-010)
Merck Sharp and Dohme
Acute and Chronic pain
1 trial -
A clinical trial of MK-7228 in adults (MK-7228-002)
Merck Sharp and Dohme
Atherosclerosis
1 trial -
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Merck Sharp and Dohme
Advanced Solid Tumors
1 trial -
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Merck Sharp and Dohme
Advanced Solid Tumors
1 trial -
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Merck Sharp and Dohme
Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).
1 trial -
M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)
Merck Sharp and Dohme
Advanced solid tumors
1 trial -
MK-1045-004
Merck Sharp and Dohme
Systemic lupus erythematosus, Rheumatoid arthritis
1 trial -
MK-2420 SAD Study
Merck Sharp and Dohme
Rheumatoid arthritis
1 trial -
MK-3214-002
Merck Sharp and Dohme
Hypercholesterolaemia
1 trial -
MK-4318 CIDF Target Engagement Study
Merck Sharp and Dohme
Pain
1 trial -
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants
Merck Sharp and Dohme
HIV infection
1 trial -
MK-4830-001
Merck Sharp and Dohme
Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)
1 trial -
MK-7091 Formulations Study in Healthy Adult Participants
Merck Sharp and Dohme
Hypercholesterolemia
1 trial -
MK-7480 Multiple Ascending Dose Study in Healthy Participants
Merck Sharp and Dohme
Non-alcoholic steatohepatitis
1 trial -
MK-8294-001
Merck Sharp and Dohme
Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer
1 trial -
MS100070_0087
Merck Sharp and Dohme
Central Nervous System Tumors
1 trial -
MS200569_0065
Merck Sharp and Dohme
Healthy
1 trial -
MS201924_0001
Merck Sharp and Dohme
Metastatic or Locally Advanced Unresectable Solid Tumors
1 trial -
MS201924_0003
Merck Sharp and Dohme
Advanced Solid Tumors
1 trial -
MS202359_0025
Merck Sharp and Dohme
Locally Advanced Squamous Cell Carcinoma of the Head and Neck
1 trial -
MS202650_0001
Merck Sharp and Dohme
Advanced solid tumors and colorectal cancer
1 trial -
MS700623_0061
Merck Sharp and Dohme
Infertility
1 trial -
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants
Merck Sharp and Dohme
Healthy
1 trial -
MK-7902-015
Merck Sharp and Dohme
Advanced/Metastatic Gastroesophageal Adenocarcinoma
1 trial
Frequently asked questions
How many clinical projects does MSD Merck Sharp have?
217 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.